Benjamin Burnett
Stock Analyst at Wells Fargo
(3.89)
# 994
Out of 5,182 analysts
107
Total ratings
56.79%
Success rate
8.8%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Benjamin Burnett
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CNTA Centessa Pharmaceuticals | Downgrades: Equal-Weight | $35 → $42 | $39.49 | +6.36% | 4 | Apr 20, 2026 | |
| INSM Insmed | Maintains: Overweight | $175 → $177 | $137.34 | +28.88% | 4 | Mar 24, 2026 | |
| AMPH Amphastar Pharmaceuticals | Maintains: Overweight | $34 → $30 | $21.65 | +38.57% | 1 | Feb 27, 2026 | |
| ALKS Alkermes | Maintains: Overweight | $37 → $43 | $34.06 | +26.25% | 4 | Feb 26, 2026 | |
| AXSM Axsome Therapeutics | Maintains: Overweight | $193 → $202 | $188.59 | +7.11% | 4 | Feb 24, 2026 | |
| FATE Fate Therapeutics | Maintains: Hold | $5 → $3 | $1.31 | +129.01% | 3 | Mar 6, 2025 | |
| CRSP CRISPR Therapeutics AG | Maintains: Hold | $53 → $49 | $51.40 | -4.67% | 6 | Feb 13, 2025 | |
| ACLX Arcellx | Maintains: Buy | $83 → $122 | - | - | 5 | Oct 18, 2024 | |
| BEAM Beam Therapeutics | Maintains: Buy | $66 → $69 | $29.80 | +131.54% | 2 | Sep 11, 2024 | |
| IDYA IDEAYA Biosciences | Maintains: Buy | $63 → $68 | $30.00 | +126.67% | 7 | Sep 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $4.4 → $4.6 | $2.29 | +100.87% | 5 | May 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $120 → $58 | $4.89 | +1,075.87% | 4 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $25 | $3.45 | +624.64% | 11 | Sep 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $690 → $780 | $7.10 | +10,885.92% | 2 | Sep 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $486 → $575 | - | - | 4 | Mar 31, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $27 → $13 | $7.17 | +81.31% | 4 | Mar 27, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $44 → $51 | $38.29 | +33.19% | 2 | Mar 23, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $43 → $46 | $35.23 | +30.57% | 2 | Mar 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $49 → $68 | $55.01 | +23.61% | 5 | Mar 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $23 → $20 | $11.11 | +80.02% | 2 | Mar 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $8 → $7 | $2.72 | +157.35% | 2 | Feb 27, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $282 → $305 | $342.70 | -11.00% | 2 | Feb 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $93 → $86 | $69.01 | +24.62% | 2 | Feb 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $65 → $45 | $24.89 | +80.80% | 1 | Dec 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $7 → $9 | $5.20 | +73.08% | 1 | Dec 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $78 → $64 | $146.95 | -56.45% | 5 | Apr 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $90 → $94 | $68.85 | +36.53% | 7 | Jan 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $7 → $10 | $4.09 | +144.50% | 3 | Jun 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $330 → $360 | $87.32 | +312.28% | 2 | Jun 28, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Hold | $16 | $0.19 | +8,224.66% | 1 | Jan 6, 2021 |
Centessa Pharmaceuticals
Apr 20, 2026
Downgrades: Equal-Weight
Price Target: $35 → $42
Current: $39.49
Upside: +6.36%
Insmed
Mar 24, 2026
Maintains: Overweight
Price Target: $175 → $177
Current: $137.34
Upside: +28.88%
Amphastar Pharmaceuticals
Feb 27, 2026
Maintains: Overweight
Price Target: $34 → $30
Current: $21.65
Upside: +38.57%
Alkermes
Feb 26, 2026
Maintains: Overweight
Price Target: $37 → $43
Current: $34.06
Upside: +26.25%
Axsome Therapeutics
Feb 24, 2026
Maintains: Overweight
Price Target: $193 → $202
Current: $188.59
Upside: +7.11%
Fate Therapeutics
Mar 6, 2025
Maintains: Hold
Price Target: $5 → $3
Current: $1.31
Upside: +129.01%
CRISPR Therapeutics AG
Feb 13, 2025
Maintains: Hold
Price Target: $53 → $49
Current: $51.40
Upside: -4.67%
Arcellx
Oct 18, 2024
Maintains: Buy
Price Target: $83 → $122
Current: -
Upside: -
Beam Therapeutics
Sep 11, 2024
Maintains: Buy
Price Target: $66 → $69
Current: $29.80
Upside: +131.54%
IDEAYA Biosciences
Sep 10, 2024
Maintains: Buy
Price Target: $63 → $68
Current: $30.00
Upside: +126.67%
May 14, 2024
Maintains: Hold
Price Target: $4.4 → $4.6
Current: $2.29
Upside: +100.87%
Apr 1, 2024
Maintains: Hold
Price Target: $120 → $58
Current: $4.89
Upside: +1,075.87%
Sep 15, 2023
Reiterates: Buy
Price Target: $25
Current: $3.45
Upside: +624.64%
Sep 10, 2021
Maintains: Buy
Price Target: $690 → $780
Current: $7.10
Upside: +10,885.92%
Mar 31, 2026
Maintains: Equal-Weight
Price Target: $486 → $575
Current: -
Upside: -
Mar 27, 2026
Maintains: Overweight
Price Target: $27 → $13
Current: $7.17
Upside: +81.31%
Mar 23, 2026
Maintains: Overweight
Price Target: $44 → $51
Current: $38.29
Upside: +33.19%
Mar 11, 2026
Maintains: Overweight
Price Target: $43 → $46
Current: $35.23
Upside: +30.57%
Mar 10, 2026
Maintains: Overweight
Price Target: $49 → $68
Current: $55.01
Upside: +23.61%
Mar 5, 2026
Maintains: Overweight
Price Target: $23 → $20
Current: $11.11
Upside: +80.02%
Feb 27, 2026
Maintains: Overweight
Price Target: $8 → $7
Current: $2.72
Upside: +157.35%
Feb 20, 2026
Maintains: Equal-Weight
Price Target: $282 → $305
Current: $342.70
Upside: -11.00%
Feb 20, 2026
Maintains: Overweight
Price Target: $93 → $86
Current: $69.01
Upside: +24.62%
Dec 30, 2025
Maintains: Overweight
Price Target: $65 → $45
Current: $24.89
Upside: +80.80%
Dec 18, 2025
Maintains: Overweight
Price Target: $7 → $9
Current: $5.20
Upside: +73.08%
Apr 1, 2025
Maintains: Buy
Price Target: $78 → $64
Current: $146.95
Upside: -56.45%
Jan 24, 2025
Maintains: Buy
Price Target: $90 → $94
Current: $68.85
Upside: +36.53%
Jun 3, 2024
Maintains: Buy
Price Target: $7 → $10
Current: $4.09
Upside: +144.50%
Jun 28, 2021
Upgrades: Buy
Price Target: $330 → $360
Current: $87.32
Upside: +312.28%
Jan 6, 2021
Initiates: Hold
Price Target: $16
Current: $0.19
Upside: +8,224.66%